Journal of Enzyme Inhibition and Medicinal Chemistry (Jan 2021)

Of mitochondrion and COVID-19

  • Khalid Omer Alfarouk,
  • Sari T. S. Alhoufie,
  • Abdelhameed Hifny,
  • Laurent Schwartz,
  • Ali S. Alqahtani,
  • Samrein B. M. Ahmed,
  • Ali M. Alqahtani,
  • Saad S. Alqahtani,
  • Abdel Khalig Muddathir,
  • Heyam Ali,
  • Adil H. H. Bashir,
  • Muntaser E. Ibrahim,
  • Maria Raffaella Greco,
  • Rosa A. Cardone,
  • Salvador Harguindey,
  • Stephan Joel Reshkin

DOI
https://doi.org/10.1080/14756366.2021.1937144
Journal volume & issue
Vol. 36, no. 1
pp. 1258 – 1266

Abstract

Read online

COVID-19, a pandemic disease caused by a viral infection, is associated with a high mortality rate. Most of the signs and symptoms, e.g. cytokine storm, electrolytes imbalances, thromboembolism, etc., are related to mitochondrial dysfunction. Therefore, targeting mitochondrion will represent a more rational treatment of COVID-19. The current work outlines how COVID-19’s signs and symptoms are related to the mitochondrion. Proper understanding of the underlying causes might enhance the opportunity to treat COVID-19.

Keywords